Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

UK SARS-COV-2 variant picks up mutation found in Brazil and South Africa 

By Brian Buntz | February 2, 2021

This colorized scanning electron microscope image shows SARS-CoV-2 (round blue objects), the virus that causes COVID-19, emerging from the surface of cells cultured in the lab. [Image courtesy of National Institute of Allergy and Infectious Diseases]

One of the most troubling mutations among SARS-CoV-2 variants is E484K. Found in the highly transmissible variants in Brazil and South Africa, the mutation may diminish vaccine efficacy and pose a higher risk of reinfection than other virus lineages.

Now, the mutation has appeared spontaneously in a portion of viral samples from Kent, Bristol and Liverpool in the U.K.

The trend is the latest evidence that the E484K mutation provides an evolutionary advantage for the novel coronavirus and that several COVID-19 variants have a similar evolutionary trajectory.

Researchers from South Africa have concluded that the E484K mutation results in a substantial reduction in the efficacy of antibodies in convalescent plasma samples. Seattle-based researchers reached similar conclusions in a preprint related to SARS-CoV-2 mutations.

COVID-19 variants

The original U.K. variant B.1.1.7 originally lacked the E484K mutation found in the South Africa B.1.351 and Brazil P.1 variants. Image courtesy of Moderna.

The U.K., South Africa and Brazil variants also share a mutation known as N501Y that could improve how the viral spike protein attaches to human cells. Fortunately, the N501Y mutation seems to influence vaccine performance less than E484K.

Moderna (NSDQ:MRNA) and Novavax (NASDAQ:NVAX) have already begun developing custom versions of their vaccines for the South Africa variant.

A growing amount of data suggest that currently available vaccines are effective against strains with the E484K mutation, albeit with reduced efficacy. The Novavax vaccine, for instance, was almost 90% effective in a Phase 3 U.K. trial when the dominant B.1.1.7 variant lacked the E484K mutation. That vaccine’s efficacy was 60% in South Africa, where the majority of SARS-CoV-2 viruses have the E484K mutation.


Filed Under: Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Icosavax
Icosavax shares positive early results for VLP vaccine candidate against RSV

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50